◀ Back to MAPK3
MAPK3 — NRG1
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Diamonti et al., Proc Natl Acad Sci U S A 2002
:
A putative dominant negative form of Nrdp1 potentiates
neuregulin stimulated
Erk1/2 activity in transfected MCF7 breast tumor cells
Yuste et al., J Biochem 2005
:
Analysis of the action of RasN17 indicated that overexpression of this mutant form of Ras did not affect
neuregulin or protein kinase C-induced
activation of
Erk1/2
Di Segni et al., J Mol Neurosci 2006
:
Taken together, these results indicate that in PC12-ErbB4 cells, the
NRG induced neuroprotective effect from MPP+ treatment, requires PI3K/PKB/Akt and
Ras/MapK signaling networks
Bernard et al., J Biol Chem 2012
(Disease Models, Animal...) :
Furthermore, in contrast to related ligands,
NRG4 enhanced cell survival but not proliferation or migration, and
stimulated phosphorylation of the anti-apoptotic mediator Akt but not ERK
MAPK
Kim et al., J Neurochem 2013
(MAP Kinase Signaling System) :
Stimulation of the ErbB receptors by
NRG1ß activated the phosphatidylinositol-3-kinase (PI3K) and
mitogen activated protein kinase ( MAPK )
Li et al., ASN neuro 2012
(Demyelinating Diseases) :
NRG1 activated
MAPK , induced c-Jun expression and promoted a loss of myelin segments in DRG explants isolated from both WT ( wild-type ) and Hsp70 KO ( knockout ) mice